Literature DB >> 17366442

[Prevention and treatment of hypotension during Caesarean delivery].

Ines Erler1, Wiebke Gogarten.   

Abstract

Regional anesthesia for Caesarean delivery is often accompanied by a reduction in maternal blood pressure. Maternal hypotension may lead to a reduction in uteroplacental blood flow with consecutive fetal acidosis. In order to avoid reductions in uteroplacental blood flow, tremendous research has been performed, showing that the avoidance of aortocaval compression, compression of the lower extremities, and prehydration with colloids are effective in reducing maternal hypotension. Further means include the recent introduction of low dose spinal anesthesia with a combination of small amounts of local anesthetics and opioids. Nevertheless, maternal hypotension is not always preventable and the use of vasopressors is still frequently required. Although ephedrine has been considered the vasopressor of choice over the last decades, current studies show that fetal acidosis is less frequently encountered with the use of phenylephrine, which should thus be considered as a first-line agent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17366442     DOI: 10.1055/s-2007-974584

Source DB:  PubMed          Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther        ISSN: 0939-2661            Impact factor:   0.698


  3 in total

1.  [Spinal anesthesia in high-volume, low-concentration technique for Caesarean sections : Retrospective analysis].

Authors:  J Jokinen; V Adametz; M Kredel; R M Muellenbach; A Hönig; A Wöckel; J Dietl; N Roewer; P Kranke
Journal:  Anaesthesist       Date:  2014-12-25       Impact factor: 1.041

2.  [Management of cardiac high risk pregnancy. Caesarean section in a primagravida with cyanotic cardiac defect].

Authors:  S Kramer; T Schröder; M Schuster; V Stangl; I Correns; W Sanad; T Volk
Journal:  Anaesthesist       Date:  2011-01       Impact factor: 1.041

3.  Burden of proof.

Authors:  Richard M Smiley
Journal:  Anesthesiology       Date:  2009-09       Impact factor: 7.892

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.